Aptus Pharma
September 23, 2025 – September 25, 2025
| Price | ₹65 - ₹70 |
| GMP Rumors * | ₹0 |
|---|---|
| Lot size | 2000 |
| Allotment | Sep 26, 2025 |
| Listing | Sep 30, 2025 |
Aptus Pharma Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| INDIVIDUAL | 2 | 4000 | 280000 | 155 |
| sHNI | 3 | 6000 | 420000 | 15 |
| bHNI | 8 | 16000 | 1120000 | 30 |
Aptus Pharma Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 528000 | 28.39% |
| QIB | 352000 | 18.92% |
| HNI | 266000 | 14.3% |
| INDIVIDUAL | 620000 | 33.33% |
| Market Maker | 94000 | 5.05% |
| Total | 1860000 | 100% |
Aptus Pharma About
IPO Details
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Fresh Issue | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
| Reserved for Market Maker | 94,000 shares (aggregating up to ₹0.6580 Cr) |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. |
Key Performance Indicators (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 44.50% | 45.18% | 20.06% |
| ROCE | 45.66% | 21.70% | 12.77% |
| EPS (BASIC) | 6.37 | 5.32 | 1.3 |
| P/E Pre IPO | 11.29 | ||
| P/E Post IPO | 15.49 |
Company Financials (In ₹Crore)
| Period | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Assets | 21.92 | 10.03 | 6.22 |
| Income | 24.64 | 17.88 | 13.90 |
| Profit | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserves | 1.97 | 1.47 | 0.67 |
| Borrowing | 10.36 | 5.31 | 2.21 |
About Company
Business: A fully integrated pharmaceutical company that manufactures and distributes a wide portfolio of 194+ formulations across acute, chronic, and wellness therapies.
Key Divisions:
Aptus Pharma: Acute therapies (e.g., antibiotics, pain management)
Aptus CD Care: Chronic therapies (e.g., cardiology, antidiabetics)
Aptus Wellcare: Wellness & nutraceuticals
Aptus Global: Exports
Competitive Advantages:
Diverse Portfolio: Covers 11+ therapeutic areas.
Strong Distribution: Network of 125+ distributors and 54+ field personnel.
Cost-Effective: Strategic manufacturing partnerships in tax-benefit states (Gujarat, Uttarakhand, Himachal Pradesh).
Office Expansion: ₹1.63 Cr for new office space & furniture.
Fuel Growth: ₹10.38 Cr for working capital to fund daily operations and sales expansion.
Strategic Flexibility: Remaining funds for general corporate purposes.
Strength
Diversified Product Portfolio: The company offers over 194 pharmaceutical formulations across 11+ therapeutic segments, enabling it to cater to a wide range of patient and healthcare needs.
Strong Distribution Network: With a central warehouse in Ahmedabad and partnerships with logistics providers, the company ensures efficient, safe, and timely delivery across its target markets.
High-Quality Standards: The company follows WHO-GMP aligned protocols and rigorous testing at every production stage, ensuring product safety, consistency, and credibility.
Weakness
Regulatory Approvals: Failure to obtain, renew, or maintain necessary statutory and regulatory permits may disrupt operations and impact results.
Customer Concentration: Dependence on a few key customers makes revenue vulnerable if contracts are reduced or terminated.
Intellectual Property Risks: Inability to protect IP or allegations of infringement may result in loss of sales, liabilities, and adverse financial impact.
Aptus Pharma Lead Manager(s)
Aptus Pharma Address
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park,
Aslali, Ahmedabad, Daskroi,
Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/